Lipocine Inc., of Salt Lake City, said it received a complete response letter (CRL) from the FDA on the new drug application for LPCN 1021, its twice-daily oral hydroxyprogesterone caproate candidate designed for testosterone replacement therapy in adult males with hypogonadism.